Navigation Links
EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
Date:10/31/2013

spect to the outlook for expectations for future financial or business performance, strategies, expectations and goals.  Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid® resulting in reduced or no royalty payments; risks associated with our product candidates; any early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).  Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition.  We caution readers not to place undue reliance on any
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Reports Second Quarter 2013 Financial Results
2. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
3. EntreMed Reports First Quarter 2013 Financial Results
4. Patent Issued In China For EntreMeds Lead Drug Candidate ENMD-2076
5. Patent Issued In U.S. For EntreMeds 2ME2 In Rheumatoid Diseases
6. EntreMed Announces Changes to Board of Directors and CEO Appointment
7. EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
8. EntreMed To Raise $10.7 Million In Registered Direct Offering
9. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
10. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
11. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Since last month,s FBI shutdown ... known as the leading online black market for illegal ... in its offering of drugs and other illegal items.  ... takedowns did succeed in lowering the numbers of drugs ... the markets in August. But some new sites that ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 /PRNewswire/ ... and Adocia (Euronext Paris: FR0011184241 – ADOC) today announced ... insulin, known as BioChaperone Lispro, for treatment in people ... relies on Adocia,s proprietary BioChaperone® technology and is currently ... will develop BioChaperone Lispro with the goal of optimizing ...
(Date:12/17/2014)... , Dec. 17, 2014 Royal Philips ... Corporation (NASDAQ: VOLC ), a global leader in ... that they have entered into a definitive merger agreement. Pursuant ... acquire all of the issued and outstanding shares of Volcano ... price of USD 1 billion (approx. EUR 800 million), to ...
Breaking Medicine Technology:Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
... 23, 2007 - Synta,Pharmaceuticals Corp., (NASDAQ: SNTA) ... commercializing small,molecule drugs to treat severe medical ... from the Phase 2b clinical,trial in metastatic ... STA-4783, will be presented at the annual ...
... - Bentley,Pharmaceuticals, Inc. (NYSE: BNT), a specialty ... abstract sponsored by,the Company has been accepted ... Association 67th Scientific Sessions in Chicago.,The abstract, ... Comparison Study of Intranasal Insulin Spray,(Nasulin(TM)) and ...
Cached Medicine Technology:Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 2Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 3Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 2Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 3
(Date:12/21/2014)... 21, 2014 Over the past 39 ... in hundreds of emergency departments across the nation, from ... have been translated into an innovative suite of tools, ... deficiencies and enhance the patient experience. , NES ... staffing and management services for hospitals, announced the development ...
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation hosted ... Whittier offices. The Hope for the Holidays Toy Drive is ... their families during the holiday season. This year, the toy ... between both offices. This event continues to be successful year ... team, store managers and assistant managers came out and not ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Weddingshe.com has ... and launched a site-wide promotion of special occasion dresses ... a popular supplier of special occasion dresses for global ... offered with big discounts, up to 80% off. Among ... Sweetheart Sequins Short Sweet 16 Dress) is very popular. ...
(Date:12/20/2014)... (HealthDay News) -- The holidays can be anything but ... fresh trees, scented candles and other allergy triggers. ... that have been packed away in dank basements or ... asthma patients," Dr. Rachna Shah, an affiliate faculty member ... in Loyola news release. Shah, who is also ...
(Date:12/20/2014)... 20, 2014 Atore, Inc, (San Francisco, ... launched first birthday focused portal on December 17th, 2014. ... launched in both US and Japan. , MERRY BIRTHDAY ... http://merrybirthday.net/message/ , MERRY BIRTHDAY MESSAGE is part ... the world. , Features, Choose from thousands of stock ...
Breaking Medicine News(10 mins):Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Atore, Inc. Releasing the First Birthday Portal 2
... both short-term and long-term survival rates , , WEDNESDAY, May ... the average survival rate for patients battling advanced colorectal ... equal measure to the advent of new, powerful drugs ... early- to mid-1990s, the average patient would have survived ...
... Fund Summer Lunch Program aims to increase participation ... 27 The Minnesota Vikings, Hunger Solutions Minnesota and ... of the Vikings Children,s Fund Summer ... will help secure up to 200,000 additional meals ...
... you look good in your swimwear this summer doesn,t ... on the importance of also making sure your digestive ... & Gamble at: http://inr.mediaseed.tv/oneClip_C/?feed=BdIundCLFxJkJuMON9VzrkWS8WHcPdMP ... photos for free and unrestricted use at ...
... Inc. ("Verus"), a specialty pharmaceutical company, announced today that ... and Tika Lakemedel AB ("Tika") in the Supreme Court ... is seeking $1.3 billion on claims of fraud, breach ... its wholly owned subsidiary Tika disregarded their obligations under ...
... Arizonans quit smoking since 2007PHOENIX, May 27 New ... shows that the rate of smoking among adults in ... points representing a 20.7 percent decrease in prevalence equating ... rate of smoking in one year dropped from ...
... W. Wirtz earmarked millions to advance research , and ... May 27 Northwestern Memorial Foundation today announced the inception ... initiative in support of continued research and clinical advancements within ... University at Northwestern Memorial Hospital. The late William ...
Cached Medicine News:Health News:More Living Longer With Advanced Colon Cancer 2Health News:More Living Longer With Advanced Colon Cancer 3Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 2Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 3Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 4Health News:Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB 2Health News:Arizona Shows More Than a 20% Drop in Smoking Rates 2Health News:Arizona Shows More Than a 20% Drop in Smoking Rates 3Health News:Arizona Shows More Than a 20% Drop in Smoking Rates 4Health News:William W. Wirtz Allocates $19.5 Million to Northwestern Memorial for Cancer Care and Research 2Health News:William W. Wirtz Allocates $19.5 Million to Northwestern Memorial for Cancer Care and Research 3Health News:William W. Wirtz Allocates $19.5 Million to Northwestern Memorial for Cancer Care and Research 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: